Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy

Milorad Tešić(University of Belgrade), Branko Beleslin(University of Belgrade), Vojislav Giga(University of Belgrade), Ivana Jovanović(Centar za Promociju Nauke), Jelena Marinković(University of Belgrade), Danijela Trifunović(University of Belgrade), Olga Petrović(University of Belgrade), Milan Dobrić(University of Belgrade), S Aleksandric(University of Belgrade), Stefan Juričić(Centar za Promociju Nauke), N Boskovic(Center for Health, Exercise and Sport Sciences), Miloje Tomašević(University of Kragujevac), Arsen Ristić(University of Belgrade), Dejan Orlić(University of Belgrade), Siniša Stojković(University of Belgrade), Vladan Vukčević(University of Belgrade), Goran Stanković(Serbian Academy of Sciences and Arts), Miodrag Ostojić(Serbian Academy of Sciences and Arts), Ana Djordjević Dikić(University of Belgrade)
Journal of the American Heart Association
October 12, 2021
Cited by 21Open Access
Full Text

Abstract

Background Microvascular dysfunction might be a major determinant of clinical deterioration and outcome in patients with hypertrophic cardiomyopathy (HCM). However, long‐term prognostic value of transthoracic Doppler echocardiography (TDE) coronary flow velocity reserve (CFVR) on clinical outcome is uncertain in HCM patients. Therefore, the aim of our study was to assess long‐term prognostic value of CFVR on clinical outcome in HCM population. Methods and Results We prospectively included 150 HCM patients (82 women; mean age 48±15 years). Patients’ clinical characteristics, echocardiographic and CFVR findings (both for left anterior descending [LAD] and posterior descending artery [PD]), were assessed in all patients. The primary outcome was a composite of: HCM related death, heart failure requiring hospitalization, sustained ventricular tachycardia and ischemic stroke. Patients were stratified into 2 subgroups depending on CFVR LAD value: Group 1 (CFVR LAD>2, [n=87]) and Group 2 (CFVR LAD≤2, [n=63]). During a median follow‐up of 88 months, 41/150 (27.3%) patients had adverse cardiac events. In Group 1, there were 8/87 (9.2%), whereas in Group 2 there were 33/63 (52.4%, P <0.001 vs. Group 1) adverse cardiac events. By Kaplan‐Meier analysis, patients with preserved CFVR LAD had significantly higher cumulative event‐free survival rate compared to patients with impaired CFVR LAD (96.4% and 90.9% versus 66.9% and 40.0%, at 5 and 8 years, respectively: log‐rank 37.2, P <0.001). Multivariable analysis identified only CFVR LAD≤2 as an independent predictor for adverse cardiac outcome (HR 6.54; 95% CI 2.83–16.30, P <0.001), while CFVR PD was not significantly associated with outcome. Conclusions In patients with HCM, impaired CFVR LAD (≤2) is a strong, independent predictor of adverse cardiac outcome. When the aim of testing is HCM risk stratification and CFVR LAD data are available, the evaluation of CFVR PD is redundant.


Related Papers

No related papers found

Powered by citation graph analysis